Histological grade, p53, HER2 and hormone receptor status of synchronous bilateral breast carcinoma

被引:18
|
作者
Matsuo K. [1 ]
Fukutomi T. [1 ]
Akashi-Tanaka S. [1 ]
Hasegawa T. [2 ]
Tsuda H. [3 ]
机构
[1] Department of Surgical Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo 104-00459, 1-1
[2] Pathology Division, National Cancer Center Research Institute
[3] Pathdogy Division, National Defense Medical College
关键词
Bilateral synchronous breast carcinoma; Estrogen receptor; HER2; p53; Progesterone receptor;
D O I
10.1007/BF02967577
中图分类号
学科分类号
摘要
Background and Objectives: Histological grade and tumor biology remain important predictors of the clinical behavior of breast carcinomas. We analyzed the clinicopathological characteristics and tumor biology with regard to histological grade (HG), p53, HER2 and hormone receptor status to address this question. Patients and Methods: A consecutive series of 74 female synchronous bilateral breast carcinoma patients treated at the National Cancer Center Hospital were the primary source of these retrospective data. Clinicopathological background factors, histological grade and immunohistochemical staining for p53, HER2 and hormone receptor status, were analyzed. Results: Of 148 synchronous bilateral tumors, 102 were invasive ductal carcinoma (IDC). The others included 24 pure or predominant ductal carcinoma in situ (DCIS), 5 spindle cell carcinomas, 16 invasive lobular carcinomas and 1 squamous cell carcinoma. 128 cases (128/148: 89%) were HG 1 (72/148: 49%) or HG 2 (56/148: 38%). The positivity rates for p53, HER2, estrogen receptor (ER) and progesterone receptor (PR) were 9% (14/148), 18% (26/148), 64% (95/148) and 64% (95/148), respectively. Conclusion: Our findings indicate that synchronous bilateral breast carcinomas showed a higher frequency of invasive lobular carcinoma, lower HG and higher rate of hormone receptor positivity than unilateral breast carcinomas.
引用
收藏
页码:127 / 133
页数:6
相关论文
共 50 条
  • [1] Differences in estrogen receptor status, HER2, and p53 comparing metachronous bilateral breast carcinoma
    Matsuo, K
    Fukutomi, T
    Tsuda, H
    Akashi-Tanaka, S
    Shimizu, C
    Hasegawa, T
    JOURNAL OF SURGICAL ONCOLOGY, 2001, 77 (01) : 31 - 34
  • [2] The effect of neoadjuvant chemotherapy on histologic grade, hormone receptor status, and Her2/neu status in breast carcinoma
    Adams, Amy L.
    Eltoum, Isam
    Krontiras, Helen
    Wang, Wenquan
    Chhieng, David C.
    BREAST JOURNAL, 2008, 14 (02): : 141 - 146
  • [3] A case of primary synchronous bilateral breast cancer with heterogenous hormone receptors and HER2 status
    Bachurska, S.
    Tashkova, D.
    Tzvetkov, P.
    Hubenova, A.
    Ilieva, R.
    VIRCHOWS ARCHIV, 2018, 473 : S201 - S201
  • [4] Comparison of histological grade, hormone receptor status and Her2 status in breast cancer pre- and post-neoadjuvant chemotherapy
    Jovanic, I.
    Milovanovic, Z.
    Zivkovic, O.
    Stojsic, J.
    VIRCHOWS ARCHIV, 2013, 463 (02) : 256 - 257
  • [5] Estrogen and progesterone receptor status, p53 and Her-2/neu protein expression in metachronous bilateral breast carcinoma (MBBC)
    Vrcel, V
    Brogi, E
    Cranor, ML
    Son, T
    Hudis, C
    Norton, L
    Tan, LK
    LABORATORY INVESTIGATION, 2002, 82 (01) : 55A - 55A
  • [6] Estrogen and progesterone receptor status, p53 and Her-2/neu protein expression in metachronous bilateral breast carcinoma (MBBC)
    Vrcel, V
    Brogi, E
    Cranor, ML
    Son, T
    Hudis, C
    Norton, L
    Tan, LK
    MODERN PATHOLOGY, 2002, 15 (01) : 55A - 55A
  • [7] P53 and HER2 neu expression in breast carcinoma occuring in young women
    Maru, D
    Middleton, LP
    Wang, S
    Valero, V
    Sahin, A
    LABORATORY INVESTIGATION, 2003, 83 (01) : 40A - 40A
  • [8] Association of p53 Overexpression with Hormone Receptor Status and Triple Negative Breast Carcinoma
    Qamar, Samina
    Khokhar, Muhammad Abbas
    Farooq, Shahid
    Ashraf, Sobia
    Humayon, Waqar A.
    Rehman, Abdul
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2019, 29 (02): : 164 - 167
  • [9] P53 and HER2 neu expression in breast carcinoma occuring in young women
    Mani, D
    Middleton, LP
    Wang, S
    Valero, V
    Sahin, A
    MODERN PATHOLOGY, 2003, 16 (01) : 40A - 40A
  • [10] The involvement of HER2 and p53 status in the regulation of telomerase in irradiated breast cancer cells
    Papanikolaou, Vassilis
    Iliopoulos, Dimitrios
    Dimou, Ioannis
    Dubos, Stephanie
    Tsougos, Ioannis
    Theodorou, Kyriaki
    Kitsiou-Tzeli, Sofia
    Tsezou, Aspasia
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2009, 35 (05) : 1141 - 1149